This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...